Navigation Links
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Date:9/26/2008

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously announced promising data from its 8-week, placebo controlled, double-blind, multi-center Phase II trial in patients with persistent stuttering which showed that pagoclone produced a statistically significant benefit in multiple primary and secondary stuttering endpoints compared to placebo. Pagoclone is a novel member of the cyclopyrrolone class of compounds and acts as a gamma amino butyric acid (GABA) selective receptor modulator.

Under the terms of the Agreement, which is subject to applicable regulatory clearances and customary conditions, Indevus will conduct and Teva will reimburse Indevus for its expenses for a Phase IIb study. The placebo- controlled study will involve approximately 300 patients with stuttering in the U.S. treated for a period of six months and is expected to commence enrollment by Q1 2009.

Following the completion of a successful Phase IIb study, the Agreement provides for Indevus to participate on a 50/50 basis with Teva in the U.S., sharing development and marketing costs, and splitting future profits, in addition to receiving milestone payments. Under certain circumstances, either party may convert the Agreement from the 50/50 arrangement to a royalty structure where Teva will be responsible for all development and commercial costs in the U.S. and Indevus would receive royalties on net sales, in addition to milestones. In either case, if the arrangement continues, Teva will be responsible for the conduct of the Ph
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
2. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
3. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
4. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
5. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
6. Indevus Announces Submission of New Drug Application
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
11. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... BOCA RATON, Fla. , July 29, 2015 ... immediate launch of Azelastine HCl Nasal Solution, 0.1%. The ... this Abbreviated New Drug Application (ANDA), which is ... Meda Pharmaceuticals. Azelastine hydrochloride nasal solution (nasal spray) ... on June 2015 IMS Health sales data.  Azelastine ...
(Date:7/29/2015)... , July 29, 2015 ... research report "Global Industry Insight: Microfluidic Devices ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles. ... Microfluidic devices  ...
(Date:7/29/2015)... , July 29, 2015 Commenting ... transaction closed, CFO Simon Dingemans reveals sales ... are performing in line with expectations. Ahead of a ... to sustainable innovation. The interview and transcript ... MerchantCantos produces in-depth interviews, documentaries and webcasts with senior ...
Breaking Medicine Technology:Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5
... The drug imatinib,mesylate, more commonly known as Gleevec(R), ... with an advanced form of chronic myeloid leukemia,(CML), according ... of the American Society of Hematology., A team ... drug,s,creator, Brian Druker, MD, followed 454 patients with chronic-phase ...
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
Cached Medicine Technology:Leukemia Drug Proves Safe and Effective Over the Long Term 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3
(Date:7/29/2015)... ... July 29, 2015 , ... The healthcare analytics market is ... region. Factors such as the rising pressure to curb healthcare costs, big data ... venture capital investments are driving market growth. Check 149 data tables & 57 ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business on ... directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same gene, ... the National academy of Sciences, and has given researchers inklings to explore Rsu1 in ...
(Date:7/29/2015)... ... 2015 , ... According to the Miami Herald on July 18th ... health disorders. Acu-detox may begin taking off in the South Florida community as more ... Although acupuncture is not a new practice, it is not widely used, but has ...
(Date:7/29/2015)... ... 29, 2015 , ... San Fernando Valley skin doctor , Dr. Peyman ... only, patients can get the complete treatment process with a 10 percent discount on ... treatment and have loose or sagging skin. , As the only non-surgical procedure ...
(Date:7/29/2015)... ... July 29, 2015 , ... Today marks a significant achievement in bringing ... growth companies and is led by a group of experienced investors, has tapped into ... with their dollars to be a part of the fund. The Sofia Fund ...
Breaking Medicine News(10 mins):Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Sofia Fund Surpasses Investor Goals 2
... test to assess chest pain is accurate in more rapid ... a heart attack. It can be caused by indigestion or ... a medical emergency, and a series of tests is given ... a heart attack.// , These tests normally take a ...
... be better than white at fending off fungi and ... it could explain why dark skin evolved in humans ... theory on why darker skin prevailed in some areas ... melanin in darker skin protects against cancer and sunburn ...
... Duke University in the United States, depression increases the ... depression and coronary artery disease is well established and ... 357 patients diagnosed with heart failure for depression. They ... suffering from major depression. Patients who were not depressed ...
... in this week’s British Medical Journal shows that bacteria with ... for ear infections can be used successfully and may help ... one of the most common bacterial infections in young children, ... is caused by the spread of Streptococcus pneumoniae and other ...
... Britain examining the relationship between increasing rates of testicular ... have infertility problems have an increased risk of developing ... of the British Medical Journal (BMJ), the study found ... the subsequent risk of testicular cancer, with men in ...
... factor for most cancers, says a Stanford University Medical Centre ... have a genetic component than those diagnosed later. , , Rare ... familial than breast and lung cancer.// The model assumed that ... of several relatively rare genes. , , The new model ...
Cached Medicine News:
... Leg Brace features a multi-axial hinge that ... without altering kinematics. The infinite degree of ... flexion and extension control of the knee. ... the tibia in correct anatomical alignment. The ...
... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy.,All Cryo/Cuffs can be ordered as ... (including a tube assembly and insulation disk). ...
... lightweight orthosis is designed to comfortably ... while allowing unobstructed motion of the ... custom fit the splint may be ... using a heat gun. One cotton ...
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
Medicine Products: